Compare BA & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BA | NVO |
|---|---|---|
| Founded | 1916 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.1B | 212.7B |
| IPO Year | N/A | N/A |
| Metric | BA | NVO |
|---|---|---|
| Price | $247.23 | $62.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 10 |
| Target Price | ★ $245.42 | $54.25 |
| AVG Volume (30 Days) | 7.0M | ★ 20.8M |
| Earning Date | 01-27-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 1.97% |
| EPS Growth | N/A | ★ 10.06 |
| EPS | N/A | ★ 3.67 |
| Revenue | ★ $80,757,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $36.46 | $7.25 |
| Revenue Next Year | $10.20 | $0.24 |
| P/E Ratio | ★ N/A | $16.45 |
| Revenue Growth | 10.18 | ★ 16.64 |
| 52 Week Low | $128.88 | $43.08 |
| 52 Week High | $248.75 | $93.80 |
| Indicator | BA | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 78.24 | 72.64 |
| Support Level | $239.60 | $56.29 |
| Resistance Level | $248.75 | $60.63 |
| Average True Range (ATR) | 5.41 | 1.44 |
| MACD | 1.85 | 0.59 |
| Stochastic Oscillator | 94.52 | 96.28 |
Boeing is a major aerospace and defense firm operating in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.